New
UPDATE: FDA is announcing a new date for the meeting. The public meeting will be held on March 8, 2021 from 10 a.m. to 2:30 p.m. EST, in a virtual (online only) format. Please save this date and time if you are interested in attending this public meeting.
US Food and Drug Administration (FDA) is conducting its first public meeting on Patient-Focused Drug Development for Vitiligo. The meeting is intended to allow FDA to obtain patient perspectives on the impact of vitiligo, including on daily life, patient views on treatment approaches, and decision factors taken into account when selecting a treatment.
Additional information about the meeting can be found on the meeting webpage. The webpage will be updated as meeting materials are developed, and registration will be available closer to the meeting date.
Please email the PFDD Staff at patientfocused@fda.hhs.gov if you have any questions.
FAQOther Questions
- How to get insurance coverage for vitiligo treatments?
Getting insurance coverage for vitiligo treatments can be challenging, but there are several steps you can take to improve your chances For a more in-depth look, check out our ...
- Vitiligo and hearing loss: any connection?
Vitiligo is primarily recognized for causing skin discoloration, but it can also impact melanocytes in unexpected areas, such as the inner ear. This raises questions about wheth...
- How can I cure vitiligo?
Currently, there is no cure for vitiligo. However, many treatments can help manage the condition by restoring skin pigmentation, halting the progression of depigmentation, and i...
Though it is not always easy to treat vitiligo, there is much to be gained by clearly understanding the diagnosis, the future implications, treatment options and their outcomes.
Many people deal with vitiligo while remaining in the public eye, maintaining a positive outlook, and having a successful career.
Copyright (C) Bodolóczki JúliaBy taking a little time to fill in the anonymous questionnaire, you can help researchers better understand and fight vitiligo.